Zidesamtinib is a medicine for a type of lung cancer that has a change in a gene called ROS1. It is taken as a pill by mouth, usually after another ROS1 medicine has stopped working. It works by blocking the ROS1 protein that helps the cancer grow.
Every report comes from a Lived member, sent anonymously.
Have you tried Jideytro (Zidesamtinib) for Non-Small Cell Lung Cancer?
Zidesamtinib, sold under the brand name Jideytro, is a prescription targeted therapy for adults with ROS1-positive non-small cell lung cancer (NSCLC) that has spread within the chest (locally advanced) or to other parts of the body (metastatic). ROS1-positive means testing of the tumor found an abnormal ROS1 gene that is driving the cancer's growth. Jideytro is approved for people whose cancer has already been treated with at least one other ROS1-targeting medicine, such as crizotinib, entrectinib, lorlatinib, repotrectinib or taletrectinib. It is not approved as a first ROS1 treatment, and its safety and effectiveness in children have not been established. One reason earlier ROS1 medicines stop working is a resistance mutation: a further change in the ROS1 gene that makes those drugs less effective. Zidesamtinib still blocks many of these altered forms, including one called G2032R, which is why it can help after other ROS1 treatments.
In ROS1-positive lung cancer, part of the ROS1 gene has become fused to another gene. The result is an abnormal ROS1 protein that works like a growth switch stuck in the on position, sending constant signals that tell cancer cells to keep growing and surviving. ROS1 is a kinase, a type of enzyme that passes on these signals. Zidesamtinib is a kinase inhibitor. It blocks the abnormal ROS1 protein, including versions carrying resistance mutations, which cuts off that growth signal and can shrink tumors. In studies it also shrank tumors that had spread to the brain.
Jideytro is a tablet taken by mouth once a day, at about the same time each day, with or without food. The usual dose is 100 mg. A 25 mg tablet also exists so the dose can be lowered if side effects become a problem. Treatment continues for as long as it is controlling the cancer and side effects remain manageable. Swallow the tablets whole. Do not split, chew, crush or dissolve them, and do not take a tablet that is broken or cracked. If a dose is missed and fewer than 12 hours have passed, take it as soon as you remember; if 12 hours or more have passed, skip it and take the next dose at the usual time. If you vomit after a dose, do not take another one; wait for the next scheduled dose. The care team may pause the medicine or lower the dose to manage side effects. Once a dose has been lowered, it is not raised again.
The most common side effects are swelling (edema); numbness or tingling in the arms or legs from nerve irritation (peripheral neuropathy); constipation; tiredness; and shortness of breath. Some people also notice changes in taste, headaches, cough, muscle or joint aches, diarrhea, rash or changes in vision. Blood tests often show higher cholesterol and triglycerides (blood fats). About a quarter of people in studies had nervous system effects. These include dizziness, unsteady walking or poor balance, memory, attention or thinking problems, confusion, trouble speaking, hallucinations, and mood changes such as anxiety, irritability or depression, rarely with thoughts of suicide. They usually began weeks to a few months into treatment. Avoid driving or operating machinery if you feel dizzy, unsteady or less mentally sharp. Tell the care team right away about new or worsening symptoms like these, or a seizure; family members should know what to watch for, since they may notice changes first. Zidesamtinib can cause serious, sometimes life-threatening lung inflammation (pneumonitis). Because lung cancer itself can cause breathing symptoms, report new or worsening shortness of breath, cough or fever to the care team right away rather than assuming it is the cancer. Pneumonia was the most common serious side effect in studies. Also call the care team right away about upper stomach pain that may spread to the back or get worse with eating, especially with nausea, which can signal inflammation of the pancreas (pancreatitis). Report unexplained muscle pain, tenderness or weakness, and any bone pain or change in how you move, because bone fractures have occurred, sometimes without a fall.
Zidesamtinib is broken down mainly by CYP3A, an enzyme that processes many medicines. Drugs that strongly or moderately block this enzyme raise zidesamtinib levels and can increase side effects; for example, itraconazole, an antifungal medicine, more than doubled the amount of zidesamtinib in the blood in a study. Drugs that speed the enzyme up can lower levels and make the treatment less effective. Both kinds should be avoided, so give the care team and pharmacist a full list of prescriptions, over-the-counter medicines, vitamins and herbal products, and check before starting anything new. Stomach-acid reducers such as lansoprazole did not meaningfully change zidesamtinib levels. The medicine can lengthen the QT interval, a measurement on an electrocardiogram (ECG, a tracing of the heart's electrical activity) that reflects how long the heart takes to reset between beats. A much longer QT raises the risk of a dangerous irregular heart rhythm. The team checks an ECG and blood salts (electrolytes) before starting and during treatment, and may check more often in people with long QT syndrome, a slow heart rhythm, heart failure or other medicines that lengthen the QT. Tell the care team right away if you feel faint or lightheaded, or your heart beats irregularly or fast. Zidesamtinib can harm a developing baby. A pregnancy test is done before starting. People who could become pregnant should use effective birth control during treatment and for 6 months after the last dose, and men with partners who could become pregnant should use it during treatment and for 3 months after. Tell the care team right away about a known or possible pregnancy. Breastfeeding is not advised during treatment or for 1 week after the last dose. The medicine may also reduce fertility in both men and women, which is worth raising before starting for anyone who may want children later.
Before the first dose, expect an ECG and blood tests for electrolytes, CPK (creatine phosphokinase, an enzyme that rises when muscle is damaged) and amylase and lipase (enzymes that rise when the pancreas is irritated). CPK is usually checked every 2 weeks in the first month and then every 1 to 2 months, and the other tests are repeated periodically. Regular scans show whether the cancer is shrinking, stable or growing. In the main study, 117 people whose cancer had already been treated with a ROS1 medicine took zidesamtinib. Tumors shrank enough to count as a response in 44% of them. A response was somewhat more likely after one earlier ROS1 drug (49%) than after two or more (38%). Among people who responded, about two in three were still responding a year later. About half of participants had cancer in the brain; among those with measurable brain tumors, the tumors shrank in 48% and disappeared on scans in 22%. The study had no comparison group, so it cannot show how much longer people live on zidesamtinib than on other options. Zidesamtinib is taken for as long as it keeps the cancer under control and side effects are manageable. Some effects, such as dizziness, often appear within the first few weeks, while others, including lung inflammation, can appear months later, so new symptoms are worth reporting throughout treatment, not just at the start.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Jideytro (Zidesamtinib), what you've noticed, or ask the community a question.